drugset / Trial / NCT00448435
Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma
RandomizedCrossoverOpen-labelTreatment
Summary
To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus fluticasone propionate DPI 50µg 1 inhalation bid in paediatric patients with asthma. To evaluate the safety of long-term treatment of GW815SF HFA MDI 25/50µg 1 inhalation bid in paediatric patients with asthma.
Timeline
- Start
- 2007-04
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluticasone propionate | Other / unclassified | 50 ug | Inhaled |
| Comparator | Salmeterol | Other / unclassified | 25 ug | Inhaled |